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Abstract
AIM: To investigate the prevalence of gastroesopha-
geal reflux disease (GERD) in patients with a laryngo-
scopic diagnosis of laryngopharyngeal reflux (LPR).
METHODS: Between May 2011 and October 2011, 41 
consecutive patients with laryngopharyngeal symptoms 
(LPS) and laryngoscopic diagnosis of LPR were empiri-
cally treated with proton pump inhibitors (PPIs) for at 
least 8 wk, and the therapeutic outcome was assessed 
through validated questionnaires (GERD impact scale, 
GIS; visual analogue scale, VAS). LPR diagnosis was 
performed by ear, nose and throat specialists using the 
reflux finding score (RFS) and reflux symptom index 
(RSI). After a 16-d wash-out from PPIs, all patients 
underwent an upper endoscopy, stationary esophageal 
manometry, 24-h multichannel intraluminal impedance 
and pH (MII-pH) esophageal monitoring. A positive 
correlation between LPR diagnosis and GERD was sup-
posed based on the presence of esophagitis (ERD), 
pathological acid exposure time (AET) in the absence 
of esophageal erosions (NERD), and a positive correla-
tion between symptoms and refluxes (hypersensitive 
esophagus, HE). 
RESULTS: The male/female ratio was 0.52 (14/27), 
the mean age ± SD was 51.5 ± 12.7 years, and the 
mean body mass index was 25.7 ± 3.4 kg/m2. All sub-
jects reported one or more LPS. Twenty-five out of 41 
patients also had typical GERD symptoms (heartburn 
and/or regurgitation). The most frequent laryngoscopic 
findings were posterior laryngeal hyperemia (38/41), 
linear indentation in the medial edge of the vocal fold 
(31/41), vocal fold nodules (6/41) and diffuse infra-
glottic oedema (25/41). The GIS analysis showed 
that 10/41 patients reported symptom relief with PPI 
therapy (P  < 0.05); conversely, 23/41 did not report 
any clinical improvement. At the same time, the VAS 
analysis showed a significant reduction in typical GERD 
symptoms after PPI therapy (P  < 0.001). A significant 
reduction in LPS symptoms. On the other hand, such 
result was not recorded for LPS. Esophagitis was de-
tected in 2/41 patients, and ineffective esophageal mo-
tility was found in 3/41 patients. The MII-pH analysis 
showed an abnormal AET in 5/41 patients (2 ERD and 
3 NERD); 11/41 patients had a normal AET and a posi-
tive association between symptoms and refluxes (HE), 
and 25/41 patients had a normal AET and a negative 
association between symptoms and refluxes (no GERD 
patients). It is noteworthy that HE patients had a posi-
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tive association with typical GERD-related symptoms. 
Gas refluxes were found more frequently in patients 
with globus (29.7 ± 3.6) and hoarseness (21.5 ± 7.4) 
than in patients with heartburn or regurgitation (7.8 ± 
6.2). Gas refluxes were positively associated with extra-
esophageal symptoms (P  < 0.05). Overall, no differenc-
es were found among the three groups of patients in 
terms of the frequency of laryngeal signs. The proximal 
reflux was abnormal in patients with ERD/NERD only. 
The differences observed by means of MII-pH analysis 
among the three subgroups of patients (ERD/NERD, 
HE, no GERD) were not demonstrated with the RSI and 
RFS. Moreover, only the number of gas refluxes was 
found to have a significant association with the RFS (P 
= 0.028 and P  = 0.026, nominal and numerical correla-
tion, respectively).
CONCLUSION: MII-pH analysis confirmed GERD diag-
nosis in less than 40% of patients with previous diag-
nosis of LPR, most likely because of the low specificity 
of the laryngoscopic findings.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is one of  the 
most common gastrointestinal disorders in Western coun-
tries[1]. The manifestations of  GERD have been recently 
classified into either esophageal or extra-esophageal 
syndromes (EES)[1]. Among the latter, Vakil et al[1] have 
included the atypical manifestations of  GERD such as 
chronic cough and laryngopharyngeal symptoms (LPS) 
(i.e., laryngitis, globus, throat discomfort), which are 
increasingly recognised by general physicians, lung spe-
cialists and ear, nose and throat (ENT) surgeons[2,3]. In 
particular, there is a large number of  data on the growing 
prevalence of  LPS in GERD patients[4-6].
Despite the recognition that GERD can provoke 
laryngeal symptoms, the diagnosis of  laryngopharyngeal 
reflux (LPR) remains a very difficult task. Initially, pa-
tients with laryngeal symptoms undergo a laryngoscopy 
and a chest X-ray to rule out malignancies. Once cancer 
is excluded, a diagnosis of  LPR is suspected. The diagno-
sis of  LPR is usually performed by ENT surgeons in case 
of  detection of  the following laryngoscopic findings: 
erythema, oedema, ventricular obliteration, post-cricoid 
hyperplasia and pseudosulcus[7]. However, these laryngo-
scopic findings are also common in healthy volunteers, 
and this largely limits their diagnostic value[7]. Moreover, 
there are several controversies regarding how to confirm 
LPR diagnosis and, more generally, EES diagnosis. Up-
per gastrointestinal endoscopy has been demonstrated 
to have low sensitivity[8,9], the proton pump inhibitor test 
has been shown to have low specificity[10], and radiologic 
studies have limited sensitivity and specificity[8]. Moreo-
ver, the sensitivity and specificity of  ambulatory pH 
monitoring as a means for diagnosing reflux in patients 
with extra-esophageal GERD symptoms have been chal-
lenged[1]. Recently, the availability of  multichannel intra-
luminal impedance and pH monitoring (MII-pH) has 
modified the diagnostic approach towards atypical mani-
festations of  GERD[11-14]. MII-pH is able to detect not 
only acid but also non-acid reflux and proximal migration 
of  the refluxate and can correlate symptoms with both 
types of  reflux[15-17]; additionally, there is a rising consen-
sus that this technique should be considered as the gold 
standard for GERD diagnosis[18]. At present, few data are 
available on the prevalence of  LPR in patients with or 
without GERD symptoms and on the characteristics of  
overall reflux episodes in those patients.
The aim of  this study was to evaluate the prevalence 
of  GERD in patients with a recent laryngoscopic diagno-
sis of  LPR by means of  MII-pH. The second endpoint 
was to assess the effectiveness of  an empirical treatment 
with proton pump inhibitors (PPIs) in patients with both 
GERD-related and non-GERD-related LPR.
MATERIALS AND METHODS
Study subjects
Between May 2011 and October 2011, 41 consecutive 
patients with LPS and an ENT diagnosis of  LPR were 
prospectively enrolled in the study. During the first visit, 
a distinct investigator completed a structured interview 
on the patients, recording a careful medical history (with 
recording of  height and weight), current medications, 
tobacco use and alcohol consumption. All patients signed 
a written informed consent form before entering into the 
study. The study was designed and carried out in accor-
dance with the Helsinki Declaration (Sixth revision, Seul 
2008).
Inclusion criteria were as follows: LPS for at least 
three consecutive months during the last year, previous 
history of  dysphonia, cough, hoarseness, throat globe 
and/or dysphagia and an ENT diagnosis of  LPR. In par-
ticular, such a diagnosis was performed after an accurate 
phoniatric and otorhinolaryngoiatric anamnesis and a 
general ENT examination with a flexible rhino-pharyn-
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go-laryngoscope with an optical fibre. The reflux findings 
score (RFS) was completed by the otolaryngologist (RFS 
> 7), suggestive value for LPR), and all patients were 
asked to complete the reflux symptom index (RSI) (RSI 
> 13, suggestive value for LPR)[19]. Patients with a RSF > 
7 and a RSI > 13 were considered affected by LPR.
Exclusion criteria were as follows: Previous surgery in 
the upper digestive tract, pregnancy and/or breastfeed-
ing, eating disorders with vomiting, underlying psychiatric 
illness, use of  non-steroidal anti-inflammatory drugs and 
aspirin, and peptic ulcer at a previous endoscopy. 
All the enrolled patients were allowed an empirical 
treatment with PPIs for at least 8 wk, and the therapeutic 
outcome was recorded through a validated questionnaire 
(GERD impact scale, GIS), which was completed before 
and after therapy[20]. The GIS comprises eight questions 
about the frequency, over the previous 2 wk, of  the fol-
lowing items: acid-related symptoms; chest pain; extra-
esophageal symptoms; impact of  symptoms on sleep, 
work, meals and social occasions; and the use of  ad-
ditional non-prescription medications. A 4-point rating 
Likert scale was used to describe the frequency of  the 
symptoms over the previous 2 wk: 0 = none (absence 
of  symptoms), 1 = mild (symptoms present for a little 
of  the time), 2 = moderate (symptoms present for some 
of  the time), and 3 = severe (symptoms present all of  
the time). Patients who responded with a score of  2 or 3 
were considered as non-responders to PPI therapy. 
The patients were also asked to rate their satisfaction 
with the symptom control on a global visual analogue 
scale (VAS) from 0 (no relief  at all) to 10 (complete 
symptom relief). The VAS score has been used as a self-
assessment tool for symptom measurement, which has 
been used in many other trials for evaluation of  ENT 
symptoms and typical and atypical GERD symptoms[21,22].
After 8 wk of  PPI therapy, all patients underwent 
upper endoscopy, stationary esophageal manometry and 
24-h MII-pH esophageal monitoring. All patients discon-
tinued PPI therapy at least 16 d before undergoing the 
planned esophageal investigations. The patients were only 
allowed to take alginates, on an as-needed basis, as rescue 
therapy. During upper gastrointestinal endoscopy, biop-
sies were taken from the gastric antrum and corpus to 
assess the presence of  Helicobacter pylori and atrophic gas-
tritis. Stationary manometry and MII-pH were performed 
after an overnight fast.
Stationary esophageal manometry
All subjects underwent stationary esophageal manometry 
to determine the distance of  the proximal border of  the 
lower esophageal sphincter (LES) from the nostrils and 
to evaluate the esophageal peristaltic wave. This study 
was performed by means of  an eight-channel water-
perfused manometric catheter with an external diameter 
of  4.5 mm (Dyno 2000® Menfis, BioMedica, Bologna 
Italy), equipped with computer-based data recording and 
storage. Esophageal body motility and LES relaxation 
were tested by at least 10 wet swallows of  5 mL of  water. 
Wave amplitude and duration were measured by means 
of  four openings located at 5, 10, 15 and 20 cm above 
the LES. A stationary pull-through technique was then 
used to accurately locate the position of  the LES.
Esophageal MII-pH
MII-pH was performed using a polyvinyl catheter (diam-
eter: 2.3 mm), equipped with an antimony pH electrode 
and several cylindrical electrodes, with a length of  4 mm, 
placed at intervals of  approximately 2 cm (Sandhill Sci-
entific Inc., Highland Ranch, CO). Each pair of  adjacent 
electrodes represented an impedance-measuring segment 
corresponding to one recording channel. The single-use 
MII-pH catheter was positioned with the pH electrode 
5 cm above the LES and the six impedance recording 
channels positioned at 3, 5, 7, 9, 15 and 17 cm above the 
LES.
The methodology of  probe calibration, catheter 
placement, patient instruction and performance has been 
previously described[23].
MII-pH data analysis
At the end of  the recording period, MII-pH tracings were 
reviewed manually to ensure accurate detection and clas-
sification of  reflux episodes. Meal periods were excluded 
from the analysis. Impedance and pH data were used to 
determine the number and type of  reflux episodes as well 
as the acid exposure time (AET) (reflux percent time) in 
each patient. In particular, the distal esophageal AET was 
defined as the total time with a pH measurement below 
4 divided by the total time of  monitoring. A percent time 
lower than 4.2% with pH < 4, over 24-h, was considered 
normal[23,24]. Reflux events were characterised according 
to previously reported criteria[25]. Total reflux number, 
esophageal AET and correlation between symptoms and 
reflux using the symptom index (SI) and symptom associ-
ation probability (SAP) were evaluated for each patient as 
previously described[26]. The symptoms were considered 
to be related to reflux if  they occurred within a 2-min 
time window after the onset of  the reflux episode[27]. For 
symptom analysis, weakly acidic and weakly alkaline re-
fluxes were pooled as non-acid reflux episodes (nadir pH 
> 4). 
Statistical analysis
MII-pH data were matched with the ENT diagnosis. Sta-
tistical analysis was performed with the Chi-squared test 
and the Fisher exact test to evaluate nominal values, and 
Pearson’s correlation was performed to explore numerical 
values. The results were considered statistically significant 
for P values < 0.05.
RESULTS
Demographic and clinical characteristics
The study evaluated 14 males and 27 females (M/F ratio 
0.52), with a mean age ± SD of  51.5 ± 12.7 years and a 
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mean body mass index of  25.7 ± 3.4 kg/m2. Eight pa-
tients out of  41 (19.5%) were current smokers (5-10 ciga-
rettes/d); 11/41 (28.8%) reported 2 to 3 units of  alcohol 
consumption per day, and 33/41 (73.3%) drank two cups 
of  coffee daily.
Symptoms
All subjects reported one or more LPS, and 25/41 pa-
tients also had typical GERD symptoms (heartburn 
and/or regurgitation). In particular, they described the 
predominant symptom (the most troublesome/frequent 
symptom during the day) and the overall most frequent 
symptoms in the last 6 mo. The predominant symptoms 
were globus 13 (31.7%), heartburn 10 (24.4%), hoarse-
ness 9 (22%), sore throat 6 (14.6%), regurgitation 2 (4.9%) 
and epigastric pain 1 (2.4%). The overall most frequent 
symptoms were globus 21 (51.2%), heartburn 15 (36.6%), 
hoarseness 14 (34.1%), sore throat 13 (31.7%), regurgita-
tion 9 (22%), dysphonia 9 (22%), belch 7 (17.1%), epigas-
tric pain 5 (12.2%), and chronic cough 3 (7.3%).
The prevalence of  symptom relief  after PPI therapy, 
evaluated with the GIS questionnaire, showed that 10/41 
(24.4%) patients reported at least one typical GERD 
symptom with “well controlled symptoms” (0) and that 
23/41 (56.1%) patients reported only LPS without any 
symptom relief. All the details regarding the prevalence 
of  symptom relief  are described in Table 1.
The VAS analysis showed a significant reduction in 
typical GERD symptoms after PPI therapy. This reduc-
tion was not recorded for LPS. All details are presented 
in Table 2.
Upper gastrointestinal endoscopy 
Upper endoscopy showed esophagitis (ERD) in 2/41 
(4.9%) patients. None of  the patients were diagnosed 
with complications of  GERD (i.e., Barrett’s esophagus, 
stenosis, adenocarcinoma). No other lesion or mucosal 
abnormality was detected during the examination.
Endoscopic hiatal hernia was found in 17/41 (41.5%) 
patients. With regard to the histological findings of  the 
corpus and antrum biopsies, 4 out of  41 (9.75%) patients 
had Helicobacter pylori infection, and no one had atrophic 
gastritis or intestinal metaplasia.
Pathophysiological esophageal investigations
Two out of  41 (4.9%) patients presented with ineffective 
esophageal motility at the stationary manometry. Thirty-
nine out of  41 (95.1%) patients did not present with ab-
normal esophageal motility.
The MII-pH analysis showed an abnormal AET in 5/41 
(12.2%) patients [2 ERD and 3 non erosive esophagitis 
(NERD)]; 11/41 (26.8%) patients had a normal AET and 
a positive SAP (hypersensitive esophagus, HE), and; 25/41 
patients had a normal AET and a negative association be-
tween symptoms and refluxes (no GERD patients). HE 
patients presented with a positive SAP for typical GERD-
related symptoms (7 heartburn and 4 regurgitation).
The percentage of  proximal reflux was abnormal (up 
more than 33%) in 4 cases with ERD/NERD (9.8%). 
Gas refluxes were found more frequently in patients 
with globus (29.7 ± 3.6) and hoarseness (21.5 ± 7.4) than 
in patients with heartburn or regurgitation (7.8 ± 6.2). 
The SAP analysis for gas refluxes was positive for extra-
esophageal symptoms. 
Laryngoscopic examination 
The most frequent laryngoscopic findings in our selected 
patients, classified by our MII-pH results, are shown in 
Table 3. Overall, no differences were found among the 
three groups of  patients in terms of  the frequency of  the 
laryngeal signs. In particular, both ERD and NERD pa-
tients did not show severe findings of  laryngeal disease.
The differences observed among the three subgroups 
of  patients (ERD/NERD, HE, no GERD) with esopha-
geal pathophysiological analysis (MII-pH) were not dem-
onstrated with the ENT symptom questionnaire (RSI) or 
with the laryngoscopic findings (RFS), as shown in Table 4.
Table 1  Results of the gastroesophageal reflux disease impact scale questionnaire before and after proton pump inhibitor therapy
How often have you had the following symptoms: 
(GIS questionnaire)
Before PPI therapy After PPI therapy P  value
Always Often Sometimes Never Always Often Sometimes Never
Pain in your chest or behind the breastbone?   1 0 0 0   0 0 1   0 NS
Burning sensation in your chest or behind the breastbone? 10 4 1 0   3 1 1 10 < 0.05
Regurgitation or acid taste  in your mouth?   2 5 2 0   1 1 3   4 < 0.05
Pain or burning in your upper stomach?   1 2 2 0   0 1 1   3 < 0.05
Sore throat or hoarseness that is related to your heartburn 
or acid reflux?
27 5 9 0 23 8 6   4 NS
NS: Not statistically significant; GIS: Gastroesophageal reflux disease impact scale; PPI: Proton pump inhibitor.
Table 2  Results of the visual analytic scale
Symptoms Pre-PPI Post-PPI P  value
Chest pain 7.1 ± 2.4 3.3 ± 0.9 0.00011
Heartburn 8.5 ± 3.2 2.3 ± 1.1 0.00011
Regurgitation 6.8 ± 1.5 4.1 ± 1.9 0.00011
Epigastric pain 5.9 ± 3.6 3.7 ± 2.4      0.0021
Hoarseness 7.4 ± 2.2 6.8 ± 2.7      0.273
Globus 9.3 ± 3.8 7.9 ± 3.5      0.087
Cough 7.9 ± 2.6 6.8 ± 2.8      0.069
Throat discomfort 8.1 ± 3.4 6.9 ± 2.1      0.058
Dysphonia 6.5 ± 2.1 5.5 ± 3.5      0.121
1Statistically significant differences. PPI: Proton pump inhibitor.
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A nominal (categorical) correlation (pathological vs 
non pathological) was performed considering endoscopic 
and esophageal pathophysiological examinations (results 
of  endoscopy, MII-pH, AET value, total number of  
reflux events, number of  proximal refluxes, gas refluxes, 
SAP). No match results were statistically significant. Only 
the number of  gas refluxes was associated with the RFS 
(P = 0.028). The numerical correlation showed the same 
results: the correlation between the RFS and gas refluxes 
was confirmed (P = 0.026). All detailed results are shown 
in Table 5.
DISCUSSION
GERD is considered an important cause of  laryngeal in-
flammation[28]. The most common symptoms of  this con-
dition, termed LPS by ENT physicians, include hoarse-
ness, throat pain, sensation of  a lump in the throat, cough 
and repetitive throat clearing. However, these symptoms 
Laryngoscopic findings Ordinal scale ERD/NERD (5) HE (11) No GERD1 (25) P  value
 Infraglottic oedema (pseudosulcus) 0 = Absent 4      10 23 0.592
2 = Present 1 1   2
Ventricular obliteration 0 = None 4 8 21 0.553
2 = Partial 1 3   4
4 = Complete 0 0   0
Erythema/hyperemia 0 = None 0 0   1 0.474
2 = Arytenoids only 2 6 15
4 = Diffuse 3 5   9
Vocal fold oedema 0 = None 3 7 19 0.375
1 = Mild 2 1   4
2 = Moderate 0 3   2
3 = Severe 0 0   0
4 = Polypoid 0 0   0
Diffuse laryngeal oedema 0 = None 0 4 10 0.271
1 = Mild 1 4   7
2 = Moderate 2 3   5
3 = Severe 2 0   3
4 = Obstructing 0 0   0
Posterior commissure hypertrophy 0 = None 0 0   0 0.763
1 = Mild 2 5 12
2 = Moderate 1 5 10
3 = Severe 2 1   3
4 = Obstructing 0 0   0
Granuloma/granulation 0 = Absent 5      10 24 0.876
2 = Present 0 1   1
Thick endolaryngeal mucus 0 = Absent 2 7 12 0.909
2 = Present 3 4 10
Table 3  Laryngoscopic findings with the reflux finding score in 41 patients with suspected laryngo-
pharyngeal reflux, classified using multichannel intraluminal impedance and pH monitoring
1Patients with normal acid exposure time and without correlation between symptoms and refluxes. ERD: Erosive 
esophagitis; NERD: Non erosive esophagitis; HE: Hypersensitive esophagus.
Table 4  Correlation between multichannel intraluminal im-
pedance and pH analysis and the reflux finding score/ reflux 
symptom index analysis
ERD/NERD HE No GERD1 P  value
AET (%)     7.4 ± 3.2   3.5 ± 1.7    1.9 ± 0.8 < 0.05
Reflux number (n) 103.2 ± 12.1 44.7 ± 6.2  35.1 ± 7.4 < 0.05
Proximal refluxes (mean %)   31 29  18 < 0.05
Acid refluxes (n)   62.5 ± 15.4 32.9 ± 5.1  19.7 ± 6.2 < 0.05
Non-acid refluxes (n)   40.1 ± 7.6 13.1 ± 4.4  15.8 ± 4.9 < 0.05
Gas refluxes (n)   11.6 ± 9.7 13.1 ± 8.1  21.7 ± 15.3 < 0.05
SAP/SI Positive Positive Negative -
RFS   10.9 ± 3.3   9.1 ± 2.7    7.6 ± 3.1 NS
RSI   14.3 ± 5.2 16.3 ± 4.7  15.8 ± 4.9 NS
1Patients with normal acid exposure time and without correlation between 
symptoms and refluxes. AET: Acid exposure time; ERD: Erosive esophagi-
tis; NERD: Non erosive esophagitis; HE: Hypersensitive esophagus. SAP/
SI: Symptom association probability/symptom index; RFS: Reflux finding 
score; RSI: Reflux symptom index; NS: Not statistically significant.
Table 5  Results of nominal and numerical correlation
Nominal 
correlation
Numerical 
correlation
RFS RSI RGE RFS RSI
AET (%) NS NS  P < 0.001 NS NS
Total reflux number NS NS  P < 0.001 NS NS
Acid reflux number NS NS  P < 0.05 NS NS
Non-acid reflux number NS NS  P < 0.05 NS NS
Proximal reflux number NS NS  P < 0.04 NS NS
SAP NS NS  P < 0.009 NS NS
Gas refluxes P = 0.028 NS      NS P = 0.026 NS
Upper endoscopy NS P < 0.001  P = 0.009 NS NS
MII-pH (diagnosis) NS NS  P < 0.001 NS NS
RFS: Reflux finding score; RSI: Reflux symptom index; RGE: Gastroesoph-
ageal reflux diagnosis; AET: Acid exposure time; NS: Not statistically 
significant; MII-pH: Multichannel intraluminal impedance and pH; SAP: 
Symptom association probability.
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are nonspecific and can also be seen in other diseases such 
as post-nasal drip syndrome or environmental exposure 
to allergens and other irritants[29]. Lundell et al[30] showed 
that acid is an uncommon cause of  LPS in the absence of  
typical reflux symptoms or endoscopic features of  reflux 
esophagitis. A similar finding was demonstrated in a more 
recent study by Ang et al[31] where 14% of  patients inves-
tigated for suspected EES showed an abnormal AET, 
suggesting that acid and non-acid refluxes do not play dif-
ferent roles in the genesis of  extra-esophageal symptoms. 
Likewise, signs of  laryngeal inflammation (i.e., hyperemia, 
oedema) are not specific to GERD. In 2007, Vavricka 
et al[32] evaluated the prevalence of  specific laryngopha-
ryngeal changes thought to be GERD-related in patients 
with known reflux disease (n = 132) vs normal subjects (n 
= 132). Ten specific hypopharyngeal and laryngeal sites 
were evaluated: the posterior pharyngeal wall, the interary-
tenoid bar, the posterior commissure, the posterior cricoid 
wall, the arytenoids complex, the true vocal folds, the false 
vocal folds, the anterior commissure, the epiglottis and 
the aryepiglottic fold. Investigators found that the preva-
lence of  laryngeal lesions was the same in both groups. 
Moreover, most signs identified in patients suspected of  
having LPR were also present in healthy subjects without 
any symptoms[33]. Milstein et al[34] performed a laryngo-
scopic evaluation of  52 non-smoking volunteers without 
any history of  ENT disease or GERD-related symptoms 
and observed the presence of  one or more signs of  tis-
sue irritation in 93% of  the subjects. Laryngoscopic or 
laryngostroboscopic examinations are determinant for 
excluding laryngeal nodules or neoplastic lesions but are 
not specific for diagnosing LPR[35]. Thus, in keeping with 
these considerations, the utility of  laryngoscopy in detect-
ing GERD-associated laryngitis remains uncertain[33,34]. 
The use of  MII-pH technology has provided new insights 
into the complex pathogenesis underlying atypical GERD 
symptoms. Based on our findings, LPS are not always 
due to GERD and RFS. Although RFS is a useful score 
for ENT, it is not able to accurately identify patients with 
LPR due to GERD. Nevertheless, in clinical practice, 
GERD is often considered as the underlying cause of  
laryngeal symptoms even in those patients who have a 
negative MII-pH or in those undergoing twice daily PPI 
therapy without any efficacy. At present, different causes 
that might be involved in the genesis of  GERD-unrelated 
LPS are not known, highlighting the need for future stud-
ies in this field. We should focus our efforts on searching 
for these other causes; reflux might be the easy answer, 
but we must look for difficult answers when logic sug-
gests that direction. Chronic laryngitis is a heterogeneous 
disease, and GERD may be just one of  the causes or an 
aggravating factor. Patients with and without troublesome 
reflux symptoms may have different pathophysiological 
mechanisms and may therefore require different therapies. 
Notably, one study demonstrated that gas refluxes 
with weak acidity were more common in patients with 
reflux-attributed laryngitis compared to GERD patients 
and controls[36]. In keeping with this finding, our results 
showed that the only characteristic of  refluxes associated 
with LPR was the presence of  gas refluxes. The mecha-
nisms by which gas refluxes may develop into LPS are 
far from being clarified. It has been hypothesised that gas 
refluxes carry aerosolised droplets containing hydrogen 
and pepsin that are able to generate troublesome symp-
toms into the proximal esophagus and pharyngeal/laryn-
geal mucosa. Indeed, microaspiration of  acid aerosolised 
droplets is considered one of  the most important mecha-
nisms for laryngeal inflammation. Hydrochloric acid 
vaporises easily and can result in a concentrated cloud of  
acidic vapour entering the airways[37]. 
An increasing number of  studies are using the pres-
ence of  pepsin in clinical samples as a marker for gas-
troesophageal reflux because it is produced exclusively 
by the stomach. Indeed, reflux has been documented by 
detection of  pepsin in the trachea, lung, sinus, middle ear, 
combined sputum and saliva, and breath condensate. Of  
note, pepsin is stable up to pH 7 and regains activity after 
reacidification[38]. In this regard, two recent review articles 
have highlighted that an immunologic pepsin assay is a 
rapid, sensitive, and specific tool for correlation of  reflux 
with airway disease and is a reliable diagnostic marker of  
EES[39,40]. In particular, extra-esophageal reflux can now 
be detected by recognising pharyngeal acidification using 
a miniaturised pH probe and by the non-invasive identifi-
cation of  pepsin in saliva and in exhaled breath conden-
sate using the pepsin immunoassay[40].
Recently, a new technology able to detect aerosols 
of  acid and gaseous clouds of  acid has been described: 
the Dx-pH measurement system (Dx-pH) (Respiratory 
Technology Corp., San Diego, CA). Dx-pH is a highly 
sensitive and minimally invasive device for the detec-
tion of  acid reflux in the posterior oropharynx. It uses 
a nasopharyngeal catheter with a sensor that is able to 
measure pH in either liquid or aerosolised droplets[41]. A 
number of  preliminary studies have suggested that this 
technique may have a role in identifying patients with 
extra-esophageal symptoms caused by reflux disease[40]. 
PPI therapy is considered to be the standard of  
care in patients with LPS when GERD is the underly-
ing suspected aetiology. In clinical practice, it is believed 
that patients with reflux-related laryngitis require more 
aggressive and prolonged PPI treatments to achieve 
an improvement of  laryngeal symptoms than those 
with typical GERD symptoms[42]. Conversely, several 
placebo-controlled trials and meta-analyses have failed to 
demonstrate any therapeutic benefit of  PPIs[43-47]. Some 
studies have shown that the proportion of  patients with 
marked improvement in laryngeal symptoms after PPI 
therapy is higher in GERD patients than in those without 
GERD[48,49]. On the other hand, the most recent multi-
center study, with 145 patients suspected of  having LPR, 
did not show any benefit in patients treated with esome-
prazole 40 mg bid for 4 mo vs placebo[43].
In the present study, patients with typical GERD 
symptoms and an abnormal AET had increased symp-
tom relief  after PPI therapy. Atypical/extra-esophageal 
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GERD-suspected symptoms are less responsive to an-
tisecretive therapy. 
In conclusion, current knowledge on LPR diagno-
sis and management needs to be expanded with new 
diagnostic techniques to better understand the underly-
ing pathophysiological mechanisms. In this respect, the 
present study underscores the importance of  MII-pH 
monitoring to assess the presence of  an established asso-
ciation between GERD and suspected LPR. 
COMMENTS
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Laryngopharyngeal reflux is defined as the reflux of gastric contents into the lar-
ynx and pharynx, and it is the most extensively investigated extra-esophageal 
syndrome with an established association with gastroesophageal reflux disease 
(GERD). It may be manifested as laryngeal symptoms as well as laryngoscopic 
findings. However, laryngoscopic findings are not specific, and this largely limits 
their diagnostic value. Moreover, there are currently several controversies re-
garding accurate confirmation of such a diagnosis. 
Research frontiers
In the area of chronic laryngitis, the research hotspot is how to diagnose and 
manage laryngopharyngeal reflux (LPR). In particular, new diagnostic tech-
niques to better understand the underlying pathophysiological mechanisms are 
necessary. Indeed, GERD may represent just one of the causes or an aggravat-
ing factor of laryngopharyngeal symptoms (LPS).
Innovations and breakthroughs
The use of esophageal multichannel impedance and pH technology has provid-
ed new insights into the complex pathogenesis underlying atypical reflux symp-
toms. In clinical practice, GERD is often considered to be the underlying cause 
of laryngeal symptoms, even in those patients who have a negative impedance 
and pH study or in those undergoing twice daily proton pump inhibitor therapy 
without any efficacy. In the present study, LPS were not always due to GERD, 
and laryngoscopic findings were not able to accurately identify patients with 
LPR due to GERD. Based on the findings, the only characteristic of refluxes as-
sociated with LPR was the presence of gas refluxes, although the mechanisms 
by which gas refluxes may contribute to LPR are far from being clarified. Over-
all, patients with typical reflux symptoms and abnormal acid exposure time had 
increased symptom relief after proton pump inhibitor therapy. Conversely, extra-
esophageal reflux-suspected symptoms were less responsive to antisecretive 
therapy. 
Applications
The present study underscores the importance of impedance and pH monitor-
ing to assess the presence of an established association between GERD and 
suspected LPR. 
Terminology
Extra-esophageal syndromes: The manifestations of GERD have been recently 
classified into either esophageal or extra-esophageal syndromes. Among the 
latter, the atypical manifestations of GERD such as chronic cough and LPS (i.e., 
laryngitis, globus, throat discomfort) have been included; Laryngopharyngeal 
reflux: Laryngopharyngeal reflux is a condition with an established association 
with GERD and is defined as the reflux of gastric contents into the larynx and 
pharynx; Multichannel intraluminal impedance and pH monitoring: This is a 
technique that is able to detect both acid and non-acid reflux and proximal mi-
gration of the refluxate, to physically characterise the refluxate (i.e., liquid, gas, 
mixed), and to correlate symptoms with each type of reflux.
Peer review
This is an interesting and well-structured study aimed to evaluate the diagnostic 
capacity of laryngoscopic findings suspected to be related to GERD, as per-
formed by ear, nose and throat physicians. The LPR definition is based on the 
symptoms, although the criteria for LPR symptoms have not been established 
by many papers. The entry number is relatively small. The authors use mul-
tichannel intraluminal impedance and pH monitoring and many questionnaires 
as the diagnostic gold standard. Of note, they found that laryngoscopic findings 
had a poor sensitivity and were not related to the multichannel intraluminal 
impedance and pH results. From their data, the authors suggested that another 
reason for LPR besides acid reflux was gas reflux.
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